The city of Los Angeles, California, currently has 379 active clinical trials seeking participants for Cancer research studies.
Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr
Recruiting
This study will be assessing the ability of PSMA-PET CT to determine the absence of clinically significant prostate cancer in patients on active surveillance (AS) with low risk and favorable intermediate-risk prostate cancer.
Gender:
Male
Ages:
Between 18 years and 90 years
Trial Updated:
03/25/2024
Locations: UCLA, Los Angeles, California
Conditions: Prostate Cancer
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
Recruiting
This is a Phase III, randomised, controlled, 3-arm, multi-centre study of neoadjuvant osimertinib as monotherapy or in combination with chemotherapy, versus SoC chemotherapy alone, for the treatment of patients with resectable EGFRm Non-Small Cell Lung Cancer
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
03/22/2024
Locations: Research Site, Los Angeles, California
Conditions: Non-Small Cell Lung Cancer
Study of INKmune in Patients With mCRPC (CaRe Prostate)
Recruiting
This is an open-label, phase I/IIa dose escalation and expansion study of INKmune in men with mCRPC. INKmune is administered to patients intravenously over three doses, at least one-week apart. The study will consist of two stages.
Gender:
Male
Ages:
18 years and above
Trial Updated:
03/22/2024
Locations: VA Greater Los Angeles Healthcare System, Los Angeles, California +1 locations
Conditions: Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC
The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)
Recruiting
The purpose of this trial is to evaluate the effectiveness and safety of the HistoSonics Edison System for the destruction of kidney tissue by treating primary solid renal tumors.
Gender:
All
Ages:
22 years and above
Trial Updated:
03/22/2024
Locations: University of Southern California, Los Angeles, California
Conditions: Renal Cancer, Tumor, Solid, Kidney Cancer, Tumor, Tumor, Benign
Converting HR+ Breast Cancer Into an Individualized Vaccine
Recruiting
Newly diagnosed post-menopausal women with clinical stage II-III, HR+HER2- breast cancer are eligible to a randomized trial, concurrently open at five US academic institutions. Patients receiving 4 months of standard neoadjuvant hormonal therapy with letrozole are randomly assigned to one of 4 arms of a trial testing focal hypo-fractionated RT alone or with immunotherapy combinations.
Gender:
Female
Ages:
Between 18 years and 90 years
Trial Updated:
03/22/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Breast Cancer
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
Recruiting
This is an open-label prospective, single institution, Phase II study of pembrolizumab in combination with radiation therapy and CSF-1R inhibition in patients with high-risk TNBC. The primary objective is to assess the pathologic complete response (pCR) rate where pCR is defined as the absence of invasive disease in the breast and lymph nodes at the time of standard of care (SOC) treatment. Secondary objectives include evaluating the change in tumor infiltrating lymphocytes (TILs), safety and to... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: TNBC - Triple-Negative Breast Cancer, Breast Cancer
Novel Lung Imaging in Adults Undergoing Radiation Therapy to Assess for Radiation Pneumonitis
Recruiting
The purpose of this study is to to compare lung function data generated by applying High Fidelity Functional Lung Imaging (HFFLI) software to 4D CT, cone beam CT, and fluoroscopic images of the lungs breathing to determine whether different modalities of imaging provide similar data on lung movement and function. HFFLI may detect changes in lung function in patients undergoing External Beam Radiotherapy for cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Lung Cancer, Breast Cancer, Mediastinum Lesion, Radiation Pneumonitis
Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study
Recruiting
This trial studies how well an interactive survivorship program works in improving healthcare resources in adolescent and young adult cancer survivors. By improving access to survivorship resources, health literacy, self-management skills, and support, an interactive survivorship program may help to improve adherence to adolescent and young adult healthcare guidelines and reduce cancer-related distress.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Conditions: Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm, Invasive Malignant Neoplasm, Leukemia, Lymphoma, Malignant Solid Neoplasm, Sarcoma, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Thyroid Gland Carcinoma
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Recruiting
This cluster-randomized comparative effectiveness trial compares a technology-based supportive cancer care (SCC) approach with a redesigned team-based supportive cancer care (SCC) approach.
Gender:
All
Ages:
21 years and above
Trial Updated:
03/20/2024
Locations: Oncology Institute for Hope and Innovation, Los Angeles, California
Conditions: End of Life, Cancer
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
Recruiting
This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: Research Site, Los Angeles, California
Conditions: Breast Cancer
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Recruiting
This is a multicenter, randomized, open-label, controlled Phase 3 trial of XL092 + atezolizumab vs regorafenib in subjects with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed during, after or are intolerant to standard-of-care (SOC) therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: Exelixis Clinical Site #77, Los Angeles, California
Conditions: Colorectal Cancer
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study
Recruiting
This is a phase 3, open label, single arm study of padeliporfin in the treatment of Upper Tract Urothelial Carcinoma (UTUC). The ENLIGHTED study will recruit patients with low-grade non-invasive upper tract urothelial carcinoma in either the kidney or the ureter. Patients will be treated with padeliporfin VTP in two phases: an Induction Treatment Phase and a Maintenance Treatment Phase and will be followed up for up to an additional 48 months in the long term (non intervention) follow up phase w... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Keck School of Medicine at USC Medical Center, Los Angeles, California
Conditions: Transitional Cell Cancer of Renal Pelvis and Ureter